Chenopodium ambrosioides has been used traditionally against parasitic diseases. The essential oil of the plant is a complex mixture of compounds with a rich structural diversity. This review focuses on recent evaluation of the essential oil from C. ambrosioides as a promising antileishmanial agent. The tested product showed activity against promastigotes and amastigotes of Leishmania amazonensis and L. donovani. An optimal dose of 30 mg/Kg was effective by intraperitoneal and oral routes in experimental cutaneous leishmaniasis. The chenopodium oil had a moderate toxicity against peritoneal macrophages of BALB/c mice and no side effects were detected in animals treated by the oral route. Isolates of L. amazonensis from treated mice were susceptible to the essential oil. Synergic effects were observed when the essential oil was incubated in conjunction with pentamidine on L. amazonensis promastigote cultures. Future studies focusing on formulation, toxicity and mechanism of action may help in the development of chenopodium oil as a new antileishmanial drug.
BaileyMS, LockwoodDNJ. (2007) Cutaneous leishmaniasis. Clinics in Dermatology, 25, 203–211.
2.
DesjeuxP. (2001) The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95, 239–243.
3.
SerenoD, CordeiroA, Mathieu-DaudeF, OuaissiA. (2007) Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitology International, 56, 3–7.
4.
BermanJ. (2005) Recent developments in leishmaniasis: Epidemiology, diagnosis and treatment. Current Opinion in Infectious Diseases, 7, 33–38.
5.
BlumJ, DesjeuxP, SchwartzE, BeckB, HatzC. (2004) Treatment of cutaneous leishmaniasis among travelers. Journal of Antimicrobial Chemotherapy, 53, 158–166.
6.
RequenaJM, IborraS, CarrionJ, AlonsoC, SotoM. (2004) Recent advances in vaccines for leishmaniasis. Expert Opinion in Biological Therapy, 4, 1505–1517.
7.
SinghS, SivakumarR. (2004) Challenges and new discoveries in the treatment of leishmaniasis. Journal of Infection and Chemotherapy, 10, 307–315.
8.
CroftSL, YardleyV. (2002) Chemotherapy of leishmaniasis. Current Opinion in Pharmaceutical Design, 8, 319–342.
9.
PinkR, HudsonA, MourièsMA, BendigM. (2005) Opportunities and challenges in antiparasitic drug discovery. Nature Review, 4, 727–740.
10.
KaminskyR. (2002) Miltefosine. Current Opinion in Investigational Drugs, 3, 550–554.
FournetA, MuñozV. (2002) Natural products as trypanocidal, antileishmanial and antimalarial Drugs. Current Topics in Medicinal Chemistry, 2, 1215–1237.
13.
FrancaF, LagoEL, MarsdenPD. (1996) Plants used in the treatment of leishmanial ulcers due to Leishmania (Vianna) braziliensis in an endemic area of Bahia, Brazil. Revista da Sociedade Brasileira de Medicina Tropical, 29, 229–232.
14.
MonzoteL, MontalvoAM, AlmanonniAS, ScullR, MirandaM, AbreuJ. (2006) Activity of the essential oil from Chenopodium ambrosioides grown in Cuba against Leishmania amazonensis.Chemotherapy, 52, 130–136.
15.
MonzoteL, GarcíaM, MontalvoAM, ScullR, MirandaM, AbreuJ. (2007) Activity of the essential oil from Chenopodium ambrosioides against Leishmania donovani.Phytotherapy Research, 21, in press.
16.
MonzoteL, MontalvoAM, ScullR, MirandaM, AbreuJ. (2007) Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: A preliminary study. Biomedicine and Pharmacotherapy, 61, 148–153.
17.
MonzoteL, MontalvoAM, ScullR, MirandaM, AbreuJ. (2007) Combined effect of the essential oil from Chenopodium ambrosioides and antileishmanial drugs on promastigotes of Leishmania amazonensis.Revista do Instituto de Medicina Tropical de São Paulo, 49, 257–260.
18.
WallaceJ. (2004) Antimicrobial properties of plant secondary metabolites. Proceedings of the Nutrition Society, 63, 621–629.
19.
KiuchiF, ItanoY, UchiyamaN, HondaG, TsubouchiA, Nakajima-ShimadaJ, AokiT. (2002) Monoterpene hydroperoxides with trypanocidal activity from Chenopodium ambrosioides.Journal of Natural Products, 65, 509–512.
20.
MacDonaldD, VanCreyK, HarrisonP, RangachariPK, RosenfeldJ, WarrenC, SorgerG. (2004) Ascaridole-less infusions of Chenopodium ambrosioides contain a nematocide(s) that is(are) not toxic to mammalian smooth muscle. Journal of Ethnopharmacology, 92, 215–221.
21.
SmillieWC, PessoaSB. (1924) A study for anthelmintic properties of the constituents of the oil of Chenopodium. Journal of Pharmacology and Experimental Therapeutics, 24, 359–370.
22.
FesterGA, MartinuzziEA, RetamarJA, RicciardiAIA. (1961) Aceites esenciales de la Replública de Argentina. Academia Nacional de Ciencias, Córdoba, 1–76.
23.
(a) VizosoA, GarcíaA, RamosA, PilotoJ, PavónV, PenichetM. (2000) Evaluación mutagénica de un extracto fluído con un menstruo etanólico al 70 % de Teloxis ambrosiodes L. Weber (Apasote). Revista Cubana de Plantas Medicinales, 5, 102–105
24.
(b) GadanoAB, GurniAA, LópezP, FerraroG, CarballoMA. (2002) In vitro genotoxic evaluation of the medicinal plant Chenopodium ambrosioides. Journal of Ethnopharmacology, 81, 11–16
25.
(c) KoutsoupakisC, GialouI, PavlidouE, KapetanakiS, VarotsisC. (2002) Antimalarial endoperoxides: synthesis and implications of the mode of action. Arkivoc, xiii, 62–69.
26.
GenestraM, EchevarriaA, Cysne-FinkelsteinL, Vignólio-AlvesL, LeonLL. (2005) Effect of amidine derivatives on nitric oxide production by Leishmania amazonensis promastigotes and axenic amastigotes. Nitric Oxide, 8, 1–6.
27.
SinghTR, SundarS. (2002) Identification of a gene linked to drug resistance in field isolates of Leshmania donovani.Annals of Tropical Medicine and Parasitology, 96, 839–841;
28.
CarrióJ, PortúsM. (2002) In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. Pharmacology, 2, 11–15.
29.
CauchetierE, LoiseauPM, LehmanJ, RivolletD, FleuryJ, AstierA, DeniauM, PaulM. (2002) Characterisation of atovaquone resistance in Leishmania infantum promastigotes. International Journal of Parasitology, 32, 1043–1051.
30.
SeifertK, MatuS, Pérez-VictoriaFJ, CastanysS, GamarroF, CroftSL. (2003) Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). International Journal of Antimicrobial Agents, 22, 380–387.
31.
BrycesonA. (2001) Current issues in the treatment of visceral leishmaniasis. Medical Microbiology and Immunology, 190, 81–84.
